Jesper Lau
After his Ph.D. in organic chemistry in 1990 at University of Southern Denmark and stay in the group of Professor Barry Trost at Standford University in California, he joined Health Care Discovery at Novo Nordisk.
Jesper Lau has 24 years experience in pharmaceutical discovery and holds a broad experience in small molecule based therapeutics as well as a comprehensive experience within protein engineering especially within diabetes care with particular interest in glucagon like peptide 1 (GLP-1). He was project manager for once weekly GLP-1 and is first inventor of semaglutide.
In addition to project management Jesper Lau has been line manager since 1995 and was in 2008 appointed Vice President of Protein and Peptide Chemistry with a staff of about 70 researchers.
Abstracts this author is presenting:
